DOI:
https://doi.org/10.7439/ijbr.v7i9.3552
Abstract
Objective: Fibroblast Growth Factor (FGF-23); a Phosphaturic peptide hormone, has recently been identified as a regulator of calcium-Phosphorus metabolism. Aim of the present study was to analyse FGF-23 in addition to the conventional indicators of bone metabolism in pre-dialytic CKD patients. METHODS: Pre-dialytic CKD Stage 1 and 2 (N=10) and Stage 3 and 4 (N=14) patients were observed for different indicators of bone metabolism including Total, intact (active) and C-terminal FGF-23 (inactive) levels at recruitment as compared to age matched controls (N=14) and as compared to their profile at six month. RESULTS: In CKD stage (1-4) patients, phosphorus levels were within normal range but showed negative correlation with eGFR (Linear correlation (r) = -0.467, p=0.021) and positive correlation with C-terminal FGF-23 levels (spearman correlation (rs) = 0.464, p=0.022). As compared to the controls, in stage 1 and 2 Total, intact and C-terminal FGF-23 increased significantly (p=0.001) by 16.4, 2.1 and 19.2 fold and in stage 3 and 4 by 28.6, 2.4 and 32.3 fold respectively. Thus, increase in the C-terminal by intact-FGF-23 in control, CKD stage 1 and 2 and CKD stage 3 and 4 were 4.5, 41.8 and 60.6 fold respectively. These patients were on regular calcium and vitamin D treatment. Follow-up study at six month did not show any change in FGF-23 levels. CONCLUSION: In the absence of hyperphosphatemia at early stages of CKD, FGF-23 levels increased with declining renal function. Increase in C-terminal FGF-23 over intact-FGF23 levels might greatly advance understanding of mineral bone disease in CKD
Downloads
Metrics
References
References:
Modi G, Jha V. Incidence of ESRD in India. Kidney Int. 2011; 79(5): 573.
Locatelli F, Cannata?And
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow, GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J of the Am Soc of Nephrol. 2004; 15(8): 2208-18.
Schmitt C P, Odenwald T, Ritz E. Calcium, calcium regulatory hormones, and calcimimetics: impact on cardiovascular mortality. Journal of the Am Soc of Nephrol.2006; 17(4 suppl 2): S78-S80.
Portale AA, Booth BE, Tsai HC, Morris Jr RC. Reduced plasma concentration of 1, 25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int. 1982; 21(4): 627-32.
Wilson L, Felsenfeld A, Drezner MK, Llach, F. Altered divalent ion metabolism in early renal failure: Role of 1, 25 (OH) 2D. Kidney Int. 1985; 27(565-573): 15.
Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant. 2002; 17(8): 1419
Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008; 35(2):329-44.
Tomasello S. Secondary hyperparathyroidism and chronic kidney disease. Diabetes Spectrum. 2008; 21(1): 19-25.
White KE, Evans WE, O’Riordan JL, Speer MC, Econs MJ, Lorenz-Depiereux B, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF-23. Nature Genet. 2000; 26(3): 345-8.
Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, et al. Human fibroblast growth factor-23 mutants suppress Na-dependent phosphate cotransport activity and 1 alpha, 25-dihydroxyvitamin D3 production. J Biol Chem. 2003; 278(4): 2206-11.
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3): 429-35.
Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int. 2004; 65(1): 1-14.
Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF-23 in CKD. Nephrol Dial Transplant. 2005; 20(7): 1295-98.
Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J of Biol Chem. 2006; 281(10): 6120-23.
Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143(8): 3179-82.
Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant. 2010; 25(12): 3983-9.
Guti
Prasad N, Jaiswal A, Kumar S, Nath M, Yadav B, Agarwal V. Fibroblast growth factor 23 and intact parathormone in post-transplant period on longitudinal follow-up. Nephrol Dial Transplant. 2015; 30(suppl 3): iii362.
Eknoyan G, Levin NW. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification-Foreword. Am J Kidney Dis. 2002; 39(2): S14-S26.
Devaraj S, Duncan-Staley C, Jialal I. Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease. Metab Syndr Relat Disord. 2010; 8(6): 477-82.
Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16(7): 2205-15.
Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71(1): 31-38.
Hoenderop JG, Bindels RJ. Is vitamin D indispensable for Ca2+ homeostasis: lessons from knockout mouse models? Nephroly Dial Transplan.t 2005; 20(5): 864-67.
Isakova T, Guti
Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo, F, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am j of kid Dis. 2004; 44(2): 250-6.
Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J of the Am Soc of Nephrol. 2010; 5(7): 1268-76.
Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2010; 107(1): 407-12.
Downloads
- PDF
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- An author must submit Copyright form After acceptance of the article.
